Viewing Study NCT02614261


Ignite Creation Date: 2025-12-24 @ 12:46 PM
Ignite Modification Date: 2026-02-01 @ 5:23 PM
Study NCT ID: NCT02614261
Status: COMPLETED
Last Update Posted: 2022-05-18
First Post: 2015-11-23
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Evaluation of Galcanezumab in the Prevention of Chronic Migraine
Sponsor: Eli Lilly and Company
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Migraine View
Keywords:

Keywords

Keyword Brief Keyword Text View
None prevention View
None prophylaxis View
None headache View